Skip to main content
Erschienen in: Hepatology International 3/2009

01.09.2009 | Original Article

The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression

verfasst von: Munechika Enjoji, Ryoko Yada, Tatsuya Fujino, Tsuyoshi Yoshimoto, Masayoshi Yada, Naohiko Harada, Nobito Higuchi, Masaki Kato, Motoyuki Kohjima, Akinobu Taketomi, Yoshihiko Maehara, Manabu Nakashima, Kazuhiro Kotoh, Makoto Nakamuta

Erschienen in: Hepatology International | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Aim

Because dyslipidemia, such as hypercholesterolemia, is a characteristic of primary biliary cirrhosis (PBC), hepatic lipid metabolism may be disturbed in PBC patients. We examined the expression of lipid metabolism-associated genes in PBC liver.

Methods

All of the patients examined were in stage I or II PBC and without medication. RNA was isolated from liver specimens by needle biopsies of PBC patients and controls. The expression levels of various genes were measured by real-time RT-PCR. Multidrug resistance 3 (MDR3) expression was examined immunohistochemically. Statistical correlations between the gene expression levels and indices of blood testing were calculated.

Results

The expression levels of sterol regulatory element-binding protein (SREBP) 2 and LDL receptor were significantly lower, and those of apolipoprotein B, microsomal triglyceride transfer protein, ATP-binding cassette G5, and liver X receptor α (LXRα) were significantly higher in the PBC liver than in the normal control liver. The expression levels of bile acid synthesis- and excretion-associated genes did not change, and those of farnesoid X receptor, peroxisome proliferator-activated receptor α, and SREBP-1c were similar between the PBC and normal liver. MDR3 gene expression levels in the PBC liver were more than 4-fold higher than those in the control liver. Immunohistochemically, strong canalicular staining for MDR3 was observed in the PBC liver. LXRα expression was positively correlated with MDR3 levels. Serum levels of γ-glutamyl transpeptidase (GGT) and IgM were negatively correlated with MDR3 levels.

Conclusions

Hepatocellular cholesterol metabolism was at least partially disturbed, even in the early stage of PBC. The most characteristic finding was a distinct elevation of MDR3 expression, and the MDR3 levels were negatively correlated with GGT and IgM levels.
Literatur
1.
Zurück zum Zitat Goldstein JL, Debose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006;124:35–46PubMedCrossRef Goldstein JL, Debose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006;124:35–46PubMedCrossRef
2.
Zurück zum Zitat Wójcicka G, Jamroz-Wiśniewska A, Horoszewicz K, Bełtowski J. Liver X receptors (LXRs); part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw 2007;61:736–759 Wójcicka G, Jamroz-Wiśniewska A, Horoszewicz K, Bełtowski J. Liver X receptors (LXRs); part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw 2007;61:736–759
3.
Zurück zum Zitat Kidambi S, Patel SB. Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review. Xenobiotica 2008;38:1119–1139PubMedCrossRef Kidambi S, Patel SB. Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review. Xenobiotica 2008;38:1119–1139PubMedCrossRef
4.
Zurück zum Zitat Kato M, Higuchi N, Enjoji M. Reduced expression of ATGL and CGI-58 in the liver may attribute to develop NAFLD in patients with insulin resistant background. Scand J Gastroenterol 2008;43:1018–1019PubMedCrossRef Kato M, Higuchi N, Enjoji M. Reduced expression of ATGL and CGI-58 in the liver may attribute to develop NAFLD in patients with insulin resistant background. Scand J Gastroenterol 2008;43:1018–1019PubMedCrossRef
5.
Zurück zum Zitat Van Erpecum KJ. Biliary lipids, water and cholesterol gallstones. Biol Cell 2005;97:815–822PubMedCrossRef Van Erpecum KJ. Biliary lipids, water and cholesterol gallstones. Biol Cell 2005;97:815–822PubMedCrossRef
6.
Zurück zum Zitat Jansen PLM, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int 2003;23:315–322PubMedCrossRef Jansen PLM, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int 2003;23:315–322PubMedCrossRef
7.
Zurück zum Zitat Oude Elfrrink RPJ, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Eur J Physiol 2007;453:601–610CrossRef Oude Elfrrink RPJ, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Eur J Physiol 2007;453:601–610CrossRef
8.
Zurück zum Zitat Matsumoto T, Miyazaki H, Nakahashi Y, Hirohara J, Seli T, Inoue K, et al. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res 2004;30:125–136PubMedCrossRef Matsumoto T, Miyazaki H, Nakahashi Y, Hirohara J, Seli T, Inoue K, et al. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res 2004;30:125–136PubMedCrossRef
9.
Zurück zum Zitat Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001;33:633–646PubMedCrossRef Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001;33:633–646PubMedCrossRef
10.
Zurück zum Zitat Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003;38:717–727PubMedCrossRef Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003;38:717–727PubMedCrossRef
11.
Zurück zum Zitat Ros JE, Libbrecht L, Geuken M, Jansen PLM, Roskams TAD. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol 2003;200:553–560PubMedCrossRef Ros JE, Libbrecht L, Geuken M, Jansen PLM, Roskams TAD. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol 2003;200:553–560PubMedCrossRef
12.
Zurück zum Zitat Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta 1999;1461:347–357PubMedCrossRef Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta 1999;1461:347–357PubMedCrossRef
13.
Zurück zum Zitat Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003;38:573–578PubMed Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003;38:573–578PubMed
14.
Zurück zum Zitat Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004;10:894–898PubMed Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004;10:894–898PubMed
15.
Zurück zum Zitat Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006;41:686–692PubMedCrossRef Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006;41:686–692PubMedCrossRef
16.
Zurück zum Zitat Chinale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, et al. Fibrate induce mdr2 gene expression and biliary phospholipids secretion in the mouse. Biochem J 1996;314:781–786 Chinale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, et al. Fibrate induce mdr2 gene expression and biliary phospholipids secretion in the mouse. Biochem J 1996;314:781–786
17.
Zurück zum Zitat Shoda J, Inada Y, Tsuji A, Kusama H, Ueda T, Ikegami T, et al. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARα-mediated redistribution of ABCB4. J Lipid Res 2004;45:1813–1825PubMedCrossRef Shoda J, Inada Y, Tsuji A, Kusama H, Ueda T, Ikegami T, et al. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARα-mediated redistribution of ABCB4. J Lipid Res 2004;45:1813–1825PubMedCrossRef
18.
Zurück zum Zitat Shoda J, Okada K, Inada Y, Kusama H, Utsunomiya H, Oda K, et al. Bezafibrate induces multidrug-resistance P-glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res 2007;37:548–556PubMedCrossRef Shoda J, Okada K, Inada Y, Kusama H, Utsunomiya H, Oda K, et al. Bezafibrate induces multidrug-resistance P-glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res 2007;37:548–556PubMedCrossRef
19.
Zurück zum Zitat Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, et al. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res 1999;16:12–18CrossRef Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, et al. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res 1999;16:12–18CrossRef
20.
Zurück zum Zitat Kuntz E, Kuntz HD. Hepatology: Principles and Practice. Berlin: Springer, 2001; 580–590 Kuntz E, Kuntz HD. Hepatology: Principles and Practice. Berlin: Springer, 2001; 580–590
21.
Zurück zum Zitat Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2004;39:779–791PubMedCrossRef Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2004;39:779–791PubMedCrossRef
22.
Zurück zum Zitat Ohishi Y, Nakamura M, Iio N, Higa S, Inayoshi M, Aiba Y, et al. Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology 2008;48:853–862PubMedCrossRef Ohishi Y, Nakamura M, Iio N, Higa S, Inayoshi M, Aiba Y, et al. Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology 2008;48:853–862PubMedCrossRef
Metadaten
Titel
The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression
verfasst von
Munechika Enjoji
Ryoko Yada
Tatsuya Fujino
Tsuyoshi Yoshimoto
Masayoshi Yada
Naohiko Harada
Nobito Higuchi
Masaki Kato
Motoyuki Kohjima
Akinobu Taketomi
Yoshihiko Maehara
Manabu Nakashima
Kazuhiro Kotoh
Makoto Nakamuta
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 3/2009
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-009-9137-y

Weitere Artikel der Ausgabe 3/2009

Hepatology International 3/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.